Given that central lowering of Aβ levels following systemic administration of future BACE1 inhibitor drugs may be limited [16], [17], it is important to determine the degree of BACE1 suppression that is required to exert therapeutic benefits including memory improvements during the progression of AD. This evidence concerns the gene BACE1 and Alzheimer disease.